NCT06600724招募中不适用
A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Evaluating PURION Processed Lyophilized Human Amnion/Chorion Membrane (ppLHACM) and Standard of Care Versus Standard of Care Alone in the Treatment of Nonhealing Diabetic Foot Ulcers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 170
- 试验地点
- 2
- 主要终点
- Percentage of target ulcers achieving wound closure
研究概览
简要总结
This study will evaluate two human amnion/chorion membrane (ppLHACM) products and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs).
详细描述
The CAMPAIGN trial is evaluating PURION Processed Lyophilized Human Amnion/Chorion Membrane (ppLHACM) and Standard of Care versus Standard of Care alone in the treatment of Nonhealing Diabetic Foot Ulcers. The study will evaluate two products, EPIEFFECT® and EPIXPRESS™, which are both ppLHACMs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age or older.
- •Diagnosis of type 1 or 2 Diabetes mellitus.
- •At randomization subjects must have a target ulcer with a minimum surface area of 0.7 cm^2 and a maximum surface area of 5.0 cm^2 measured post debridement.
- •The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care, prior to the initial screening visit.
- •The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus.
- •The target ulcer must be Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. The ulcer may not include exposed tendon or bone.
- •The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:
- •Ankle-Brachial Index (ABI) between 0.7 and ≤ 1.3;
- •Toe-Brachial Index (TBI) ≥ 0.6;
- •Transcutaneous Oxygen Measurement (TCOM) ≥ 40 mmHg;
- •Pulse Volume Resistance (PVR): biphasic.
- •If the potential subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.
- •Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to enrollment.
- •The potential subject must consent to using the prescribed offloading method for the duration of the study.
- •The potential subject must agree to attend the weekly study visits required by the protocol.
- •The potential subject must be willing and able to participate in the informed consent process.
排除标准
- •The potential subject is known to have a life expectancy of < 6 months.
- •The potential subject's target ulcer is not secondary to diabetes.
- •The target ulcer is infected or there is cellulitis in the surrounding skin.
- •The target ulcer exposes tendon or bone.
- •There is evidence of osteomyelitis complicating the target ulcer.
- •There is an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.
- •The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).
- •The potential subject is taking hydroxyurea.
- •The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.
- •The potential subject with a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.
- •The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.
- •The surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). MolecuLight Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).
- •The surface area measurement of the Target ulcer decreases by 20% or more during the 2-week screening phase: the 2 weeks from the initial screening visit (S1) to the TV-1 visit during which time the potential subject received SOC.
- •The potential subject has an acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.
- •Women who are pregnant or considering becoming pregnant within the next 6 months are excluded.
- •The potential subject has end stage renal disease requiring dialysis.
- •Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.
- •A potential subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
- •The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.
- •The potential subject has a malnutrition indicator score <17 as measured on the Mini Nutritional Assessment.
- •A subject has a wound with active or latent infection is excluded.
- •A subject with a disorder that would create unacceptable risk of post-operative complications is excluded.
- •A subject with a known sensitivity to aminoglycoside antibiotics is excluded.
结局指标
主要结局
Percentage of target ulcers achieving wound closure
时间窗: 1 - 12 weeks
The percentage of target ulcers achieving complete wound closure in 12 weeks.
次要结局
- Percent of wound closure area(1 - 12 weeks)
- Adverse Events(1 - 12 weeks)
- Change in Pain in Target Ulcer(1 - 12 weeks)
- Change in Quality of Life(1 - 12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
Clinical Studies of Endometrial Cytology and Cervical Methylation Assays in Endometrial Cancer Screening and Fertility-Preservation EvaluationEndometrial CancerMethylationCytologyFertility PreservationScreening ToolLiquid BiopsyNon-invasiveNCT06672341Yulan Ren200
招募中
3 期
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 MutationsNon-Small Cell Lung Cancer With HER2- MutationsNCT06430437Jiangsu HengRui Medicine Co., Ltd.300
撤回
1 期
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)Blood Platelet DisorderHematologic DiseasesPurpura, ThrombocytopenicPurpuraBlood Coagulation DisorderThrombotic MicroangiopathiesHemorrhagic DisordersAutoimmune DiseasesImmune System DiseasesHemorrhagePathologic ProcessesSkin ManifestationsPurpura, Thrombocytopenic, IdiopathicPrimary Immune ThrombocytopeniaITP - Immune ThrombocytopeniaThrombocytopeniaImmune ThrombocytopeniaNCT06291415Hutchmed48
已完成
3 期
A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic SuspensionOtitis ExternaNCT00980876Farmoquimica S.A.224
招募中
2 期
PanACEA - STEP2C -01Other Specified Pulmonary TuberculosisPulmonary TuberculosisNCT05807399Michael Hoelscher390